T2* MRI Analysis for Sarcoma
- Conditions
- RadiotherapySarcomaMagnetic Resonance Imaging
- Registration Number
- NCT03658343
- Lead Sponsor
- Bryan Allen
- Brief Summary
T2\* imaging is a method to identify labile iron pools in tumor cells. These iron pools may be linked to better treatment outcomes for specific types of therapy. This is a small pilot study to see if radiation therapy changes the amount of iron in a sarcoma tumor.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
- pathologically confirmed Sarcoma, by biopsy or excision
- prescribed radiation therapy as per standard of care
- treatment to begin within 5 weeks after surgery or biopsy
- ECOG 0, 1, or 2
- ability and willingness to provide informed consent
- < 18 years of age
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in ferric iron levels detected by T2* MRI baseline and 8 weeks Change from baseline in Fe3+ iron levels
- Secondary Outcome Measures
Name Time Method Change in ferrous iron levels detected by T2* MRI Baseline and 8 weeks Change from baseline in Fe2+ iron levels
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Holden Comprehensive Cancer Center
🇺🇸Iowa City, Iowa, United States
Holden Comprehensive Cancer Center🇺🇸Iowa City, Iowa, United States